Biomarkers and severe asthma: a critical appraisal

Severe asthma (SA) is a clinically and etiologically heterogeneous respiratory disease which affects among 5-10 % of asthmatic patients. Despite high-dose therapy, a large patients percentage is not fully controlled and has a poor quality of life. In this review, we describe the biomarkers actually...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and molecular allergy CMA 2015-10, Vol.13 (1), p.20-20, Article 20
Main Authors: Chiappori, Alessandra, De Ferrari, Laura, Folli, Chiara, Mauri, Pierluigi, Riccio, Anna Maria, Canonica, Giorgio Walter
Format: Article
Language:English
Subjects:
Asthma
Biological markers
Care and treatment
Development and progression
Health aspects
Monoclonal antibodies
Nitric oxide
Review
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Severe asthma (SA) is a clinically and etiologically heterogeneous respiratory disease which affects among 5-10 % of asthmatic patients. Despite high-dose therapy, a large patients percentage is not fully controlled and has a poor quality of life. In this review, we describe the biomarkers actually known in scientific literature and used in clinical practice for SA assessment and management: neutrophils, eosinophils, periostin, fractional exhaled nitric oxide, exhaled breath condensate and galectins. Moreover, we give an overview on clinical and biological features characterizing severe asthma, paying special attention to the potential use of these ones as reliable markers. We finally underline the need to define different biomarkers panels to select patients affected by severe asthma for specific and personalized therapeutic approach.
ISSN:1476-7961
1476-7961
DOI:10.1186/s12948-015-0027-7